We are live on ! Find out more
IMUX icon

Immunic

65 hedge funds and large institutions have $51.1M invested in Immunic in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more call options, than puts

Call options by funds: $859K | Put options by funds: $421K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

7% more funds holding

Funds holding: 6165 (+4)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.54% less ownership

Funds ownership: 6.22%5.67% (-0.54%)

45% less capital invested

Capital invested by funds: $92.4M → $51.1M (-$41.3M)

Holders
65
Holders Change
+4
Holders Change %
+6.56%
% of All Funds
0.86%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
11
Increased
20
Reduced
16
Closed
6
Calls
$859K
Puts
$421K
Net Calls
+$438K
Net Calls Change
+$1.02M
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$8.9M
APM
2
Avidity Partners Management
Texas
$7.97M -$377K -29,960 -4%
SCM
3
Soleus Capital Management
Connecticut
$7.29M
RI
4
RTW Investments
New York
$4.57M
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.92M -$978K -77,626 -17%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$2.69M -$3.04M -241,020 -47%
Focus Partners Wealth
7
Focus Partners Wealth
Massachusetts
$2.17M +$29.7K +2,361 +1%
OFM
8
Omega Fund Management
Massachusetts
$1.79M
IC
9
Ikarian Capital
Texas
$1.61M +$1.41M +112,067 +227%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$1.4M -$5.29M -419,581 -75%
Morgan Stanley
11
Morgan Stanley
New York
$1.1M +$900K +71,405 +183%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$953K +$8.52K +676 +0.7%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$884K +$217K +17,193 +24%
BlackRock
14
BlackRock
New York
$784K +$125K +9,955 +15%
6CM
15
683 Capital Management
New York
$700K +$19.3K +1,535 +2%
Millennium Management
16
Millennium Management
New York
$580K +$605K +47,984 +481%
Renaissance Technologies
17
Renaissance Technologies
New York
$567K +$224K +17,754 +46%
BFM
18
Boothbay Fund Management
New York
$425K +$2.25K +179 +0.4%
Marshall Wace
19
Marshall Wace
United Kingdom
$418K -$61K -4,841 -10%
State Street
20
State Street
Massachusetts
$304K +$172K +13,680 +82%
Northern Trust
21
Northern Trust
Illinois
$231K -$466 -37 -0.2%
BCM
22
Bridgeway Capital Management
Texas
$215K +$28K +2,220 +12%
UOC
23
UBS O'Connor
Illinois
$205K +$122K +9,689 +90%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$166K -$11.6K -920 -5%
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$159K +$71.7K +5,691 +56%

IMUX Hedge Fund Activity: Q4 2024 in Review

65 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2024, worth a combined $51.1M — down 45% from $92.4M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new IMUX positions and 6 closed out — a net gain of 5 holders — while 20 added to existing stakes and 16 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $1.41M. The largest seller was Adage Capital Partners, cutting an estimated $5.29M.

  • 65 institutional investors held Immunic (IMUX) as of Q4 2024, up from 61 in Q3 2024.
  • Funds reported $51.1M of Immunic stock for Q4 2024, down 45% quarter-over-quarter.
  • 11 funds opened new Immunic positions in Q4 2024 and 6 closed out, a net change of +5 holders.
  • The largest Immunic buyer in Q4 2024 was Ikarian Capital, an estimated $1.41M added.
  • The largest Immunic seller in Q4 2024 was Adage Capital Partners, an estimated $5.29M sold.

Based on aggregated 13F filings for Q4 2024.